北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第一临床医学院  > 学位论文
学科主题: 内科学
题名:
帕立骨化醇不同给药方式治疗继发性甲状旁腺功能亢进症的对照研究
作者: 郝娟
答辩日期: 2016-07-19
导师: 左力
专业: 内科学
授予单位: 北京大学
授予地点: 北京大学第一临床医学院
学位: 硕士
关键词: 帕立骨化醇 ; 继发性甲状旁腺功能亢进症 ; 给药方式
其他题名: Comparative Efficacy and Safety of Different Paricalcitol Regimens on Secondary Hyperparathyroidism in Hemodialysis Patients: A retrospective study
分类号: R581.1
摘要:

目的:探讨帕立骨化醇(Paricalcitol,PCT)不同给药方式治疗透析患者合并继发性甲状旁腺功能亢进症(secondary hyperparathyroidism,SHPT)的有效性及安全性。 方法:维持性血液透析合并SHPT患者32例随机分为US组(美国批准的方案:起始剂量按0.04ug/kg给药)和EU组(欧洲批准方案:起始剂量全段甲状旁腺激素(iPTH)(pg/mL)/80ug给药), 经2-4周的洗脱后开始给药,US组15例,PCT起始剂量:0.04ug/kg,每周三次;EU组17例,PCT起始剂量:全段甲状旁腺激素(intact parathyroid hormone,iPTH)(pg/mL)/80ug,每周三次,共治疗12周,两组患者均根据血iPTH或钙、磷水平每两周调整剂量,停药后观察4周。比较两组患者iPTH达标率(连续两次测定iPTH较基线下降>30%)的差异评估有效性,观察两组并发不良事件(高钙血症、高磷血症、高钙磷乘积、甲状旁腺功能减退及暂时停药)的差异评估安全性。 结果:EU组和US组达标率相似(88.2% vs.73.3%,P>0.05),起始剂量较大的EU组,治疗期间帕立骨化醇的剂量呈递减趋势,治疗前期(前六周前)因并发不良事件而暂时停药的风险也相应升高(高磷血症47.1% vs.42.2%,P<0.05,高钙磷乘积58.8% vs.37.8%,P<0.05),而起始剂量较小的US组,治疗期间帕立骨化醇的剂量呈递增趋势,治疗后期(后六周)更易因并发不良事件而暂时停药(高磷血症44.4% vs.27.5%,P<0.05;高钙磷乘积60.0% vs.35.3%,P<0.05),差异均有统计学意义。 结论:帕立骨化醇可明显降低继发甲状旁腺功能亢进透析患者的iPTH水平, 但剂量较高时仍有并发高钙、高磷血症的风险而需调整剂量或暂时停药,须根据患者具体情况选择不同的给药方式及个体化剂量以获得最佳的临床疗效。 【关键词】帕立骨化醇;继发性甲状旁腺功能亢进症;给药方式;

英文摘要:

Objective:The objectives of this study were to examine efficacy and safety of two dosing regimens of ive vitamin D receptor activator paricalcitol in the treatment of secondary hyperparathyroidism of maintenance hemodialysis patients.

Methods: This retrospective study recruited 32 maintenance hemodialysis patients with secondary hyperparathyroidism. Patients were randomized to two treatment arms by initial dose of paricalcitolpackage (PI): USgroup(initialdose:0.04ug/kg)and EU group(initial dose:iPTH(pg/mL)/80ug). After a wash out period of 2-4 weeks, they received different initial doses of US or EU three times weekly for 12 weeks and onemonth follow-up after drug withdrawal. And adjusted the dose of paricalcitol biweekly according to the serumiPTH, calcium (Ca) and phosphorus (P) levels in themonitoring weeks.Finally evaluated the efficacy and safety of paricalcitol in comparison with two groups in the primary endpoint of two consecutive ≥ 30% iPTH decreases and tendency to adverse effects including hypercalcemia, hypoerphosphatemia, elevated Ca-P product, hypoparathyroidism and drug suspension.

Results: The effective rate of two groups was similar, and no inferiority was demonstrated (88.2% vs. 73.3%, P>0.05). In the prior 6 weeks,EU group, with the relatively higher initial dose, was more likely to induce adverse events and withdrawal due to adverse events than US group(Hypercalcaemia:47.1% of EU vs. 42.2% of US,elevatedCa-P product:58.5% of EU vs. 37.8% of US).In the posterior 6 weeks, US group, with increasing cumulative dose, was more likely to induce adverse events and withdrawal due to adverse events than EU group (Hypoercalcaemia:44.4% of US vs.27.5% of EU, elevated Ca-P product:60.0%of  US vs.35.3% of EU).Both were statistically significant, P<0.05.

 

Conclusions: Both EU and US PI paricalcitol dosing strategies effectively reduced iPTH levels in Chinese subjects with SHPT, with minimal impact on Ca and P levels. But patients with higher dose of paricalcitol have increased risk of dose adjustment and drug withdrawal due to adverse events Including hypercalcaemia, hypophosphatemia, elevated Ca-P product and hypoparathyroidism. In order to get the best clinical benefits of paricalcitol, different initial dose and personalized regimen is required.

Keywords: Paricalcitol, Secondary Hyperparathyroidism, Regimens

语种: 中文
相关网址: 查看原文
内容类型: 学位论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/125268
Appears in Collections:北京大学第一临床医学院_学位论文

Files in This Item:

There are no files associated with this item.


作者单位: 北京大学第一临床医学院

Recommended Citation:
郝娟. 帕立骨化醇不同给药方式治疗继发性甲状旁腺功能亢进症的对照研究[D]. 北京大学第一临床医学院. 北京大学. 2016.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[郝娟]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[郝娟]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace